GLP1_NEW
Liraglutide after insulin degludec injection
LIRAGL_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -8.13 (-13.76 to -2.18) | 0.95 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.91 (1.30 to 34.63) | 0.14 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.09 (0.00 to 0.92) | 0.92 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.25 (0.00 to 7.52) | 0.82 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.25 (0.00 to 6.41) | 0.76 |